Compare Eli Lilly And Co (LLY) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Altria Group Inc — how do they compare? Eli Lilly And Co trades at $1,177.77 (market cap $1.04T), while Altria Group Inc trades at $71.54 (market cap $119.25B). The key difference: Eli Lilly And Co is far larger — about 8.7× Altria Group Inc's market cap, and Altria Group Inc pays the higher dividend (6.22%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Altria Group Inc for 154 Days on average.
| LLY | MO | |
|---|---|---|
Market Cap | $1.04T | $119.25B |
Volume | 3,064,878 | 11,178,169 |
Sector | Health | Consumer Staples |
52-Week High | $1.28K | $74.92 |
52-Week Low | $799.57 | $54.72 |
Typical Hold Time | 93 Days | 154 Days |
Enterprise Value | $1.09T | $141.46B |
Dividend Yield | 0.59% | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Altria Group (MO) trades at $71.68, up 3.31% with a bullish technical signal supported by moving averages. The stock shows strong profitability with 72.24% gross margins and 39% net income margin, though revenue has declined from $20.7B in 2022 to $20.1B in 2025. Recent earnings show mixed results with one beat and two misses in the last four quarters. The company maintains a substantial dividend yield with 60 consecutive increases, supported by $9.3B in operating cash flow.
MO presents a high-yield opportunity with analyst consensus favoring Buy ratings (61.5%), but faces significant risks including negative shareholder equity, declining margins, and regulatory pressures. The stock trades below the $69.71 consensus price target, suggesting limited upside potential. Investors must weigh the attractive 6.6% dividend yield against fundamental challenges in the core tobacco business and balance sheet concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
